Cencora (COR) Q4 2026 Earnings
Adjusted EPS excludes Q4 items including $177.4 million of acquisition and divestiture-related deal and integration expenses, $116.0 million acquisition-related intangibles amortization, and tax discrete items. The tax items include an $87.1 million tax benefit related to the pending MWI Animal Health divestiture and a $146.8 million unfavorable Swiss deferred tax asset valuation adjustment. GAAP diluted EPS was $2.71.
How Did COR Stock React to Q4 2026 Earnings?
Did COR Beat Earnings? Q4 2026 Results
Yes. Cencora reported Q4 2026 earnings of $4.66 a share on Nov 4, 2026, beating the $4.57 consensus estimate by 1.9%. Revenue was $88.4B against a $87.9B estimate.
Cencora closed its fiscal fourth quarter on a confident note, posting adjusted EPS of $4.66 against a consensus estimate of $4.58, a 1.88% beat that extended the drug distribution giant's winning streak to five consecutive quarters of topping Wall Street expectations. Revenue of $88.35 billion rose 5.5% year over year, edging past the $87.91 billion consensus by 0.50%, with the February 2026 acquisition of OneOncology emerging as the clearest driver of the quarter's strength. The oncology platform lifted gross margin by 55 basis points to 4.08% and helped push U.S. Healthcare Solutions operating income up 22.0% to $997.63 million, as higher-margin specialty and management services work more than offset the dilutive effect of surging GLP-1 drug volumes. GAAP diluted EPS came in at $2.71, shaped by discrete tax items including an $87.10 million benefit tied to the pending MWI Animal Health divestiture and a $146.80 million unfavorable Swiss deferred tax adjustment. Looking ahead, management guided fiscal 2027 adjusted EPS to $19.40 to $19.75, implying 8% to 10% growth, alongside a price target recently lifted to $377 by analysts ahead of the report.
- February 2026 acquisition of OneOncology lifted U.S. Healthcare Solutions gross profit margin
- Unit volume growth, including increased specialty product sales to health systems and physician practices
- Increased sales of GLP-1 products for diabetes and/or weight loss (lower margin)
- International growth across all businesses, especially Canadian and global specialty logistics
- Other segment growth at Profarma and MWI Animal Health; lower MWI depreciation due to held-for-sale classification
- Prior-year comparison included a $723.9 million PharmaLex goodwill impairment
- Share repurchases reduced diluted share count
“Fiscal 2026 was a pivotal year for Cencora, as we expanded our MSO platform through the acquisition of OneOncology, sharpened the focus of our portfolio and delivered record results.”
Cencora CEO, on the earnings call
What Is Cencora's Outlook?
Fiscal 2027 adjusted (non-GAAP) guidance: - **Adjusted diluted EPS:** $19.40 to $19.75, reflecting 8% to 10% growth. - **Revenue:** 3% to 5% growth overall. Pharmaceutical Distribution and Services 4% to 6%; Specialty Pharmaceutical and Provider Services 9% to 14%; Other about $3.5B. - **Adjusted operating income:** 4% to 6% growth overall. Pharmaceutical Distribution and Services 2% to 4%; Specialty Pharmaceutical and Provider Services 18% to 21%; Other about $200M. - **Net interest expense:** $490M to $510M. - **Adjusted effective tax rate:** about 20%. - **Diluted shares:** about 190M. - **Adjusted free cash flow:** about $3.5B. - **Capital expenditures:** about $1.0B. Guidance assumes the Profarma stake sale closes in fiscal Q1 and the MWI Animal Health merger with Covetrus closes March 31, 2027. Long-term targets reaffirmed: - Adjusted operating income growth of 7% to 10%. - Adjusted diluted EPS growth of 10% to 14%. - Capital deployment contribution of 3% to 4%. - New segment targets: mid-single-digit operating income growth for Pharmaceutical Distribution and Services and mid-teens growth for Specialty Pharmaceutical and Provider Services.
COR YoY Financials
| Metric | Q4 2026 | Q4 2025 | Year over year |
|---|---|---|---|
| Revenue | $88.4B | $83.7B | +5.5% |
| Gross Profit | $3.6B | $2.6B | +38.3% |
| Operating Income | $906.8M | $854.6M | +6.1% |
| Net Income | $519.4M | $147.2M | +252.9% |
COR Revenue by Segment
When Does Cencora Report Next?
Figures from SEC filings and company reports. Not investment advice.